Pyrefin was founded to develop novel small molecule anti-inflammatory drug candidates. Company founders have characterized the role of the EP2 receptor for prostaglandin E2 as a major mediator of neuroinflammation, and synthesized hundreds of highly selective and potent antagonists of the receptor. Pyrefin has selected candidates from this portfolio for their superior pharmacologic, pharmacokinetic and toxicologic profiles, and established proof of concept in animal models of neuro- and peripheral inflammation. The Company is focused on establishing clinical proof of concept for acute neuroinflammatory indications with achievable development criteria, initially in post-operative delirium. Pyrefin is seeking initial investment to advance its lead candidate into the clinic. The Company envisions multiple potential exit opportunities thereafter. The Company has operations in the Research Triangle region of North Carolina, with headquarters in Atlanta, GA.